11.23
price down icon3.77%   -0.44
after-market Handel nachbörslich: 11.23
loading
Schlusskurs vom Vortag:
$11.67
Offen:
$11.63
24-Stunden-Volumen:
1.02M
Relative Volume:
1.24
Marktkapitalisierung:
$614.05M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-8.7054
EPS:
-1.29
Netto-Cashflow:
$-33.83M
1W Leistung:
-6.96%
1M Leistung:
+20.36%
6M Leistung:
+39.68%
1J Leistung:
+80.26%
1-Tages-Spanne:
Value
$11.10
$11.71
1-Wochen-Bereich:
Value
$11.10
$12.21
52-Wochen-Spanne:
Value
$5.45
$13.16

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name
Firmenname
Zevra Therapeutics Inc
Name
Telefon
(321) 939-3416
Name
Adresse
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Name
Mitarbeiter
59
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-11
Name
Neueste SEC-Einreichungen
Name
ZVRA's Discussions on Twitter

Vergleichen Sie ZVRA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ZVRA
Zevra Therapeutics Inc
11.23 638.11M 27.46M -46.05M -33.83M -1.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-02 Eingeleitet H.C. Wainwright Buy
2025-01-08 Fortgesetzt Cantor Fitzgerald Overweight
2024-10-07 Eingeleitet Guggenheim Buy
2024-09-24 Eingeleitet JMP Securities Mkt Outperform
2024-09-24 Bestätigt Maxim Group Buy
2024-04-02 Bestätigt Maxim Group Buy
2024-03-12 Eingeleitet William Blair Outperform
2023-03-17 Eingeleitet Maxim Group Buy
Alle ansehen

Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten

pulisher
03:22 AM

What drives Zevra Therapeutics Inc. stock priceOutstanding stock performance - PrintWeekIndia

03:22 AM
pulisher
03:03 AM

What analysts say about Zevra Therapeutics Inc. stockSuperior stock growth - PrintWeekIndia

03:03 AM
pulisher
Jul 23, 2025

Zevra Therapeutics Inc. Stock Analysis and ForecastExplosive wealth accumulation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Is Zevra Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 18, 2025

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Zevra Therapeutics: Promising Growth Driven by Miplyffa Success and Strategic Focus on Rare Diseases - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

ZVRA Showcases Key Findings on MIPLYFFA and OLPRUVA at Genetics - GuruFocus

Jul 18, 2025
pulisher
Jul 18, 2025

Zevra Therapeutics Highlights Research on MIPLYFFA® and OLPRUVA® at 42nd Annual SERGG Meeting - Nasdaq

Jul 18, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail

Jul 17, 2025
pulisher
Jul 17, 2025

William Blair Issues Optimistic Forecast for ZVRA Earnings - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

Zevra Therapeutics' MIPLYFFA: A Paradigm Shift in Rare Disease Treatment - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

5 Small Drug Stocks To Buy Amid Trump's New Tariff Threats - Barchart.com

Jul 16, 2025
pulisher
Jul 16, 2025

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism - The Manila Times

Jul 16, 2025
pulisher
Jul 16, 2025

Breakthrough: New Clinical Data Shows MIPLYFFA Halts Rare Brain Disease Progression for 5 Years - Stock Titan

Jul 16, 2025
pulisher
Jul 16, 2025

Niemann-Pick Disease Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

ZVRA Publishes Positive Long-term Results for Arimoclomol in NPC Treatment | ZVRA Stock News - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

Why Zevra Therapeutics Inc. stock attracts strong analyst attentionEarly Buy Suggestion - newser.com

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Zevra Therapeutics Inc. stock price move sharplyHigh Yield Stock Selection - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA) - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

How Zevra Therapeutics Inc. stock performs during market volatilityBreakout Momentum Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Buy” from Analysts - Defense World

Jul 15, 2025
pulisher
Jul 14, 2025

Cantor Fitzgerald Issues Positive Outlook for ZVRA Earnings - Defense World

Jul 14, 2025
pulisher
Jul 12, 2025

Cantor Fitzgerald Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street Zen - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) - GlobeNewswire

Jul 12, 2025
pulisher
Jul 11, 2025

Zevra(ZVRA) Soars 4.41% on Phase 2 Trial, Strategic Collaboration - AInvest

Jul 11, 2025

Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):